
    
      Primary Objective: The primary objective of this study is to assess the effect of 12 weeks of
      initial treatment with bavituximab versus PEG-IFN, each combined with ribavirin, on plasma
      HCV RNA level in patients with chronic HCV genotype 1 infection.
    
  